ABSTRACT-It has been reported that there is a continuous release of nitric oxide (NO) that contributes to the regulation of vascular tone in the arterial system. In contrast, the role of NO on vascular tone in the venous system is controversial. We examined the effect of IVY-nitro-L-arginine (LNNA), an NO synthase in hibitor, on venous tone in dogs. Venous tone was evaluated by effective vascular stiffness (EVS), which was calculated from the changes in central venous pressure recorded simultaneously with changes in blood volume. LNNA (10 mg/kg, i.v.) increased EVS from 0.21 ±0.04 to 0.30±0.03 mmHgl kg/ml as well as in creasing the systemic vascular resistance. N -Nitro-D-arginine had no effect on EVS. The LNNA-induced in crease in EVS was partly reversed by L-arginine, but not by D-arginine, indicating that the increase in EVS was attributable to a blockade of NO synthesis. Since the present study was conducted under ganglion blockade, nitroxidergic nerve terminals do not seem to be the source of NO in this case. These findings sug gest that NO (endothelium-derived relaxing factor) is constantly released in the venous system and con tributes to the regulation of total systemic venous tone.
It has been suggested that there is a continuous release of nitric oxide (NO) that contributes to the regulation of vascular tone in the arterial system. This thesis is based on data showing that the blockade of NO synthesis induced a constriction in rabbit aorta ring (1) , an increase in perfu sion pressure in the isolated perfused heart (2), and an increase in blood pressure in vivo (3) . In contrast, there does not appear to be a continuous release of NO in the venous system (4) . In humans, the blockade of NO synthe sis induced a vasoconstriction in the brachial artery but not in the hand veins (5, 6) . In hamsters, it caused a reduc tion in the diameter of the arterioles but not in the venules of the cheek pouch (7) . However, these studies are confined to a small part of the venous system. Since the venous system may play an important role in the regula tion of cardiac output by affecting the filling of the heart, one must know the effect of the blockade of NO synthesis on the vascular tone of the systemic venous system (8) .
The purpose of this study was to investigate whether blockade of NO synthesis with 1V°-nitro-L-arginine (LNNA) alters systemic venous tone in dogs. One common method to monitor systemic venous tone is the mean circulatory filling pressure (9) , but it requires a cessation of cardiac output and may considerably affect the basal conditions of the cardiovascular system. In contrast, effective vascu lar stiffness (EVS) reported by Miinzel et al. (10) was cal culated from the changes in central venous pressure recorded simultaneously with artificial changes in blood volume and does not require the cessation of cardiac out put. By using this method, we evaluated the role of NO in the regulation of the basal vascular tone in systemic capacitance vessels.
MATERIALS AND METHODS

Animal preparation
Mongrel dogs of either sex were anesthetized with pentobarbital sodium (30 mg/kg initial and 3 mg/kg/hr maintenance, i.v. Reflexes were minimized by hexamethonium chloride (10 mg/kg and 10 mg/kg/hr, i.v.). This dose of hexa methonium abolished the reflex tachycardia produced by intravenous injection of 10 pg/kg of nitroglycerin (in crease in heart rate by 49 ± 12 beats/min during the con trol period and 3±2 beats/min following hexamethon ium infusion, n=4). Heparin was administered intra venously (500 units/kg and 250 units/kg/hr, i.v.). To reverse the hypotension and venous collapse induced by hexamethonium, saline and dextran 40 (average molecu lar weight of 40 K dalton, 10010 w/v) were both infused continuously at a rate of 2.5 ml/kg/hr after an initial infu sion of 10 ml/kg during the equilibration time.
Measurement of effective vascular stiffness EVS was measured according to Miinzel et al. (10) . Dextran (4 ml/kg) was given to replace an equal volume of blood, which was stored in a water bath at 371C. The stored blood was infused into the abdominal aorta through the femoral artery catheter at a rate of 2 ml/kg/min for 2 min with a Masterflex pump equipped with a quick loading head (model 7520-25 and 7021-20; Cole-Parmer Instrument Co., Chicago, IL, USA). After 1 min, an equal volume was withdrawn at the same rate for 2 min. After another min, the withdrawal procedure was repeated and followed by reinfusion in an identical manner. Thus, the total cycle time was 11 min and the blood volume was changed four times. The central venous pressure was plotted every min against the volume change, and a regression line was drawn (Fig. 1) . The slope of this line was defined as EVS (unit: mmHg kg/ml). Compliance is regarded as the inverse of EVS.
Protocol
Dogs were divided into three groups. In the first group (n=4) and second group (n=4), LNNA (total 10 mg/kg) was intravenously infused for 30 min after one hr of equilibration. Thirty minutes after cessation of LNNA in fusion, 500 mg/kg of L-arginine was infused for another 30 min to the dogs in the first group. Dogs in the second group were given D-arginine instead of L-arginine. To ex amine if the action of LNNA is stereospecific, lV' -nitro-D arginine (DNNA) (total of 10 mg/kg) was infused instead of LNNA in the third group (n=4), and the effect of DNNA on EVS and other hemodynamic parameters were assessed. EVS was measured during the control period, 15 min after the cessation of L(D)NNA infusion and just after cessation of L(D)-arginine. Other parameters were continuously recorded. The same doses of LNNA and L arginine were used for the inhibition and disinhibition of NO synthase in anesthetized dogs (11) .
Statistics
Data were expressed as the mean±S.E.M. One-way analysis of variance was used to compare the data ob tained from multiple groups of dogs and a randomized blocked analysis of variance was used to analyze the data for the time course effects. Individual comparisons were made with the Duncan multiple comparison test. A value of P<0.05 was considered statistically significant.
Drugs
The following drugs were dissolved in 0.9010 saline and administered intravenously: 1VG-nitro-L-arginine and 1VG nitro-D-arginine (Peptide Institute, Inc., Osaka); L-argi nine monohydrochloride and pentobarbital sodium (Tokyo Chemical Industry, Tokyo); D-arginine mono hydrochloride, heparin sodium, and hexamethonium chloride (Wako Pure Chemical Industries, Ltd., Osaka). Dextran 40 was a kind gift from Green Cross, Osaka.
RESULTS
The control values of each measured parameter are shown for each group in Table  1 . There were no sig nificant differences in these values. (Fig. 4) . The cardiac output was reduced by the infusion of LNNA from 1.66±0.30 to 1.05± 0.12 1/min at 30 min and 0.82--E0.07 1/min at 60 min. L-Arginine had a tendency to restore the cardiac out put which recovered to 0.99±0.04 1/min at 90 min, but this change was not statistically significant compared to the value at 60 min (Fig. 4) . Systemic vascular resistance was increased by LNNA from 88.2± 16.6 to 152.7±23.5 mmHg min/l at 30 min, and further increased to 172.6 ± 18.5 mmHg . min/l at 60 min, even though blood pressure was restored to the control level at this point. L-Arginine significantly decreased the systemic vascular resistance to 120.5 ± 9.5 mmHg min/l at 90 min (Fig. 4) .
Effect of LNNA and D-arginine on hemodynamic param eters (group 2)
The infusion of LNNA induced almost the same effect on blood pressure, cardiac output, systemic vascular resis tance and EVS as in group 1. In contrast to L-arginine, however, the infusion of D-arginine did not restore the LNNA-induced changes of these parameters (Figs. 3 and  4) .
Effect of DNNA on hemodynamic parameters (group 3)
DNNA had no significant effects on blood pressure, cardiac output, systemic vascular resistance or EVS (Figs. 3 and 4) . 
DISCUSSION
The present study demonstrated that LNNA increased EVS as well as systemic vascular resistance. DNNA did not show such effects. These changes lasted after the cessa tion of LNNA infusion and were significantly reversed by L-arginine infusion, but not by D-arginine infusion. These data, together with our previous finding that LNNA in hibits acetylcholine-induced vasodilation in dogs (12) , in dicate that these hemodynamic changes caused by LNNA are attributable to a blockade of NO synthesis.
EVS (10, 13) mainly reflects the total systemic venous tone, but several limitations must be considered: (1) The increase in systemic vascular resistance and the reduction in cardiac output induced by LNNA may diminish vascu lar compliance and hence increase EVS. However, previ ous studies (13, 14) have shown that these changes were in dependent of EVS. (2) LNNA-induced increase in central venous pressure may also alter EVS. This notion is unlike ly, since the regression between volume change and cen tral venous pressure during the control period compared to that obtained after LNNA infusion (Figs. 1 and 2 ) was, for the most part, in the same range of central venous pressures; and in this pressure range, LNNA increased EVS at the same pressure level. (3) Redistribution of blood flow following LNNA administration also may affect the measured EVS value. For example, if LNNA selectively constricts arterioles to high capacitance (low stiffness) areas, such as the splanchnic region, blood will shift to other regions where the capacitance is low, and EVS will therefore increase. However, this does not seem to be the case, because LNNA was reported to reduce the blood flows of renal, mesenteric, femoral, and carotid arteries to the same extent (15) . These findings, taken together, suggest that the LNNA-induced increase in EVS was mainly due to venoconstriction, and that NO is con stantly released in capacitance vessels and regulates their basal tone.
A possible origin of constant NO release is the endo thelium and/or nitroxidergic neurons. The synthesis of NO has been associated with stimulation of a2-adrener gic, muscarinic, and thrombin receptors on venous endo thelial cells (16) , indicating the presence of NO syn thase, which may constantly release NO in capacitance vessels. Another possible candidate for the source of con stant NO release is nitroxidergic nerve endings (17) . The contribution of these neurons, however, may be minor in the present study, since ganglion blockade was performed with infusion of hexamethonium, which has been shown to abolish vasorelaxation induced by nitroxidergic nerve transmission (18) . Thus, in this model, NO is probably released under basal conditions as endothelium-derived relaxing factor (EDRF).
Although systemic vascular resistance remained high af ter the cessation of LNNA infusion, blood pressure grad ually declined and returned to the control levels at 60 min. This spontaneous decline of blood pressure was not found in rabbits, where the pressor effect of NO synthesis inhibition is long-lasting (7, 12) . The mechanism under lying this difference is unclear, but may be attributable to cardiac depression induced by LNNA in dogs (19) .
In conclusion, the present study demonstrated that (1) NO regulates the total systemic venous tone in dogs and that (2) the source of NO in this case was most probably EDRF, not nitroxidergic nerve terminals.
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